4-Methylpyrazolo[1,5-a][1,3,5]triazine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并三嗪类
• 英文名称: 4-Methylpyrazolo[1,5-a][1,3,5]triazine
• 化学式: C₆H₆N₄
• 分子量: 134.14
• InChiKey: BCBUXJMMCCUIIC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  43.1
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• HETEROCYCLIC COMPOUNDS AND USES THEREOF
  申请人：Ren Pingda

  公开号：US20120122838A1

  公开（公告）日：2012-05-17

  Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.

  调节激酶活性的化合物和药物组合物，包括PI3激酶活性，以及与激酶活性相关的疾病和病况的化合物、药物组合物和治疗方法在此进行描述。
• PROPHYLACTIC OR THERAPEUTIC AGENT FOR DISEASES OF POSTERIOR SEGMENT OF EYE
  申请人：Santen Pharmaceutical Co., Ltd

  公开号：EP3170500A1

  公开（公告）日：2017-05-24

  The present invention relates to a prophylactic or therapeutic agent for a posterior ocular disease, which comprises a compound represented by formula (1) below: its enantiomer or diastereomer, or a pharmaceutically acceptable salt thereof (hereinbelow also referred to as the "present compound") as an active ingredient.

  本发明涉及一种眼后疾病的预防或治疗剂，它由下式（1）所代表的化合物组成： 其对映体或非对映体，或其药学上可接受的盐（以下也称为 "本化合物"）作为活性成分。
• Heterocyclic compounds that inhibit the kinase activity of Mnk useful for treating various cancers
  申请人：eFFECTOR Therapeutics, Inc.

  公开号：US10000487B2

  公开（公告）日：2018-06-19

  The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula IA or Formula IB, as well as stereoisomers, tautomers or pharmaceutically acceptable salts thereof. For Formula IA and Formula IB compounds A1, A2, A3, A4, W1, W2, Y, X, R1, R2, R3, R4a, R4b, R5a, R5b, R6, R7, R8, R9, R9a, R9b, R10 and subscript n are as defined in the specification. The inventive Formula IA and Formula IB compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

  本发明提供了符合式 IA 或式 IB 的化合物及其立体异构体、同系物或药学上可接受的盐的合成、药学上可接受的制剂和用途。 对于式 IA 和式 IB 化合物 A1、A2、A3、A4、W1、W2、Y、X、R1、R2、R3、R4a、R4b、R5a、R5b、R6、R7、R8、R9、R9a、R9b、R10 和下标 n 如说明书中所定义。本发明的式IA和式IB化合物是Mnk的抑制剂，可用于各种治疗应用，包括但不限于炎症和各种癌症的治疗。
• US8901133B2
  申请人：——

  公开号：US8901133B2

  公开（公告）日：2014-12-02
• US8969363B2
  申请人：——

  公开号：US8969363B2

  公开（公告）日：2015-03-03